Clinical Trials Logo

Thrombocytopenia clinical trials

View clinical trials related to Thrombocytopenia.

Filter by:

NCT ID: NCT04516967 Active, not recruiting - Clinical trials for Immune Thrombocytopenia

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

Start date: March 5, 2021
Phase: Phase 3
Study type: Interventional

A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months

NCT ID: NCT04516837 Recruiting - Clinical trials for Immune Thrombocytopenia

Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)

Start date: August 31, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective, multicenter, randomized, open-label study to investigate the efficacy and safety of eltrombopag plus recombinant human thrombopoietin (rhTPO) versus eltrombopag as treatment for corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) during the COVID-19 pandemic.

NCT ID: NCT04481282 Recruiting - Clinical trials for Immune Thrombocytopenia

The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Start date: July 8, 2020
Phase: Phase 2
Study type: Interventional

Single-arm, open-label, single center study to assess the efficacy and safety of terbutaline plus danazol in patients with corticosteroid resistant/relapsed ITP.

NCT ID: NCT04478227 Active, not recruiting - Thrombocytopenia Clinical Trials

TPO-Mimetic Use in Children for Hematopoietic Failure

Start date: August 18, 2020
Phase: Early Phase 1
Study type: Interventional

This is an open label, prospective Pilot interventional study will investigate the safety and efficacy of Romiplostim, thrombopoietin (TPO) mimetic, in children (ages: 0 to 21 years) with broad scope of bone marrow failure disorders including acquired and inherited conditions as a first line of therapy along with standard of care.

NCT ID: NCT04437953 Withdrawn - Cancer Clinical Trials

Avatrombopag for Thrombocytopenia in People With Cancer

Start date: May 27, 2020
Phase: Phase 2
Study type: Interventional

This study will test whether avatrombopag is an effective treatment for thrombocytopenia in people who have both cancer and a liver disease (such as cirrhosis, cholangitis, or hepatitis). Researchers will look at whether giving participants avatrombopag for 3 weeks can raise their platelet levels enough for them to begin chemotherapy. The study will also test whether avatrombopag can continue to be effective against thrombocytopenia while participants are on chemotherapy for 12 weeks or longer. In addition, researchers will determine how safe the study drug is in participants.

NCT ID: NCT04420494 Recruiting - Clinical trials for Umbilical Cord Blood

Umbilical Cord Blood Treatment for Refractory Immune Cytopenia

Start date: April 20, 2022
Phase: N/A
Study type: Interventional

Immune-related hematocytopenia is a type of immunity Inflammatory cytopenia-mediated diseases, hormones and immunosuppressants are its first-line treatment. However, conventional immunosuppressants are ineffective or have a high recurrence rate. And some patients are not effective for these treatments, due to infection of blood cells, bleeding, decreased quality of life, and even severe death. There is currently no effective method for such patients. This study intends to recruit IRIC patients, give cord blood infusion, observe its efficacy and safety, and detect changes in inflammation-related indicators before and after treatment. There are no relevant reports at China and abroad. This study can provide new treatment options for patients with IRIC.

NCT ID: NCT04371939 Recruiting - Clinical trials for Wiskott-Aldrich Syndrome

Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

Start date: November 5, 2019
Phase: Phase 2
Study type: Interventional

This is a prospective, open-label, randomized, two-arm clinical trial conducted to evaluate the safety and efficacy of romiplostim in comparison with eltrombopag in the treatment of thrombocytopenia in patients with Wiskott-Aldrich syndrome

NCT ID: NCT04368598 Recruiting - Clinical trials for Immune Thrombocytopenia

The Combination of High-dose Dexamethasone and Acetylcysteine as the Treatment of Newly-diagnosed ITP

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

A single-arm, open-label study to evaluate the efficacy and safety of Acetylcysteine plus high-dose Dexamethasone in adults newly diagnosed with primary immune thrombocytopenia (ITP).

NCT ID: NCT04350164 Completed - Clinical trials for Wiskott-Aldrich Syndrome

Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

Start date: April 1, 2012
Phase:
Study type: Observational

The rationale for this retrospective study is to evaluate the efficacy and safety of thrombopoietin-receptor agonist (TPO-RA) romiplostim for reducing thrombocytopenia and bleeding tendency in pediatric participants with genetically confirmed Wiskott-Aldrich syndrome (WAS).

NCT ID: NCT04348799 Completed - Clinical trials for Bronchopulmonary Dysplasia

Thrombocytopoiesis and Platelet Homeostasis in Infants With Bronchoplumonary Dysplasia

BPD
Start date: January 1, 2019
Phase:
Study type: Observational

To investigate the relationship between bronchopulmonary dysplasia and thrombocytopenia.